Patent assignee · US · COMPANY

Biodesix, Inc.

🏢 View company profile →
50Patents
50Active
50Granted
56Portfolio score

Filing activity: Mar 31, 2006 → Sep 2, 2022 · 10 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US7736905B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 47 Active
US7879620B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 19 Active
US7858389B2 Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway Emerging Cross-Sectional Technologies 19 Active
US7858390B2 Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway Emerging Cross-Sectional Technologies 17 Active
US7906342B2 Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 16 Active
US9477906B2 Classification generation method using combination of mini-classifiers with regularization and uses thereof Electricity 16 Active
US7867775B2 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway Emerging Cross-Sectional Technologies 15 Active
US8097469B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 14 Active
US9279798B2 Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof Electricity 11 Active
US8718996B2 Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents Emerging Cross-Sectional Technologies 11 Active
US10489550B2 Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample Electricity 10 Active
US8024282B2 Method for reliable classification of samples in clinical diagnostics using an improved method of classification Physics 10 Active
US8467988B1 Method and system for validation of mass spectrometer machine performance Electricity 9 Active
US8914238B2 Method for predicting breast cancer patient response to endocrine therapy Electricity 7 Active
US9563744B1 Method of predicting development and severity of graft-versus-host disease Electricity 6 Active
US8119418B2 Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 6 Active
US8119417B2 Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 6 Active
US9824182B2 Method and system for determining whether a drug will be effective on a patient with a disease Emerging Cross-Sectional Technologies 6 Active
US9211314B2 Treatment selection for lung cancer patients using mass spectrum of blood-based sample Electricity 5 Active
US10007766B2 Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods Physics 5 Active
US10217620B2 Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry Emerging Cross-Sectional Technologies 4 Active
US8586379B2 Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Emerging Cross-Sectional Technologies 4 Active
US10713590B2 Bagged filtering method for selection and deselection of features for classification Physics 4 Active
US9779204B2 Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample Electricity 4 Active
US9254120B2 Method for predicting breast cancer patient response to combination therapy Electricity 4 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.